$4.56
+0.06 (+1.33%)
Open$4.48
Previous Close$4.50
Day High$4.70
Day Low$4.22
52W High$5.38
52W Low$1.91
Volume—
Avg Volume439.3K
Market Cap181.78M
P/E Ratio—
EPS$-4.33
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+360.5% upside
Current
$4.56
$4.56
Target
$21.00
$21.00
$13.91
$21.00 avg
$28.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.03M | 5.08M | 4.69M |
| Net Income | 1.10M | 914.1K | 814.2K |
| Profit Margin | 21.9% | 18.0% | 17.4% |
| EBITDA | 1.45M | 1.42M | 1.49M |
| Free Cash Flow | 1.19M | 761.6K | 738.1K |
| Rev Growth | -9.3% | +7.5% | +3.9% |
| Debt/Equity | 1.05 | 1.23 | 1.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |